➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Merck
McKinsey
Baxter
Boehringer Ingelheim
AstraZeneca

Last Updated: July 11, 2020

DrugPatentWatch Database Preview

Patent: 9,066,963

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,066,963
Title:Methods of treating breast cancer with anthracycline therapy
Abstract: The application describes methods for screening subjects with breast cancer to determine if the breast cancer will be responsive to a breast cancer therapy including an anthracycline. The application also describes methods for treating subjects with breast cancer by screening them for the likelihood of the effectiveness of treating the cancer with a therapy including anthracycline and administering the therapy in subjects when it is found that anthracycline is likely to be effective.
Inventor(s): Perou; Charles M. (Carrboro, NC), Ellis; Matthew J. (St. Louis, MO), Bernard; Philip S. (Salt Lake City, UT), Nielsen; Torsten O. (North Vancouver, CA)
Assignee: The University of North Carolina at Chapel Hill (Chapel Hill, NC) Washington University (St. Louis, MO) University of Utah Research Foundation (Salt Lake City, UT) British Columbia Cancer Agency Branch (Vancouver, British Columbia, CA)
Application Number:13/421,367
Patent Claims:see list of patent claims

Details for Patent 9,066,963

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial The University of North Carolina at Chapel Hill (Chapel Hill, NC) Washington University (St. Louis, MO) University of Utah Research Foundation (Salt Lake City, UT) British Columbia Cancer Agency Branch (Vancouver, British Columbia, CA) 2031-03-15 RX search
Amgen XGEVA denosumab INJECTABLE; SUBCUTANEOUS 125320 002 2010-06-01   Start Trial The University of North Carolina at Chapel Hill (Chapel Hill, NC) Washington University (St. Louis, MO) University of Utah Research Foundation (Salt Lake City, UT) British Columbia Cancer Agency Branch (Vancouver, British Columbia, CA) 2031-03-15 RX Orphan search
Amgen PROLIA denosumab INJECTABLE; SUBCUTANEOUS 125320 001 2010-06-01   Start Trial The University of North Carolina at Chapel Hill (Chapel Hill, NC) Washington University (St. Louis, MO) University of Utah Research Foundation (Salt Lake City, UT) British Columbia Cancer Agency Branch (Vancouver, British Columbia, CA) 2031-03-15 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial The University of North Carolina at Chapel Hill (Chapel Hill, NC) Washington University (St. Louis, MO) University of Utah Research Foundation (Salt Lake City, UT) British Columbia Cancer Agency Branch (Vancouver, British Columbia, CA) 2031-03-15 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
AstraZeneca
McKinsey
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.